Doses studied
Selank dosage: what the research administered
The doses, routes, and formulations used in studies — reported as research context, never as a recommendation.
Read this first
This page describes what researchers gave to animals and patients in studies — it is not a guide for taking Selank, and nothing here is a human dose. Selank dosage in the literature falls into a few buckets. In rats and mice, studies typically used roughly 100 to 300 micrograms per kilogram of body weight, given by injection or into the nose. In Russian clinical work, the form was a 0.15% liquid sprayed or dropped into the nose, used over courses of a few weeks. There is no FDA-approved dose because Selank is not FDA-approved. Because the peptide breaks down quickly in the body, the question of how often it is given matters as much as how much — and that is covered on the half-life page. Throughout, this is study description, not advice.
Selank dosage in animal studies
Rodent studies most often used doses in the range of about 100 to 300 µg/kg. The clearest anchor is the rat GABA gene-expression study, which administered a single 300 µg/kg dose and measured shifts in 45 genes at one hour and 22 at three hours [4]. Mouse studies of behavior and enkephalinase activity used intraperitoneal research doses, with effects that varied by strain phenotype [20]. These figures describe what was administered to which species by which route — they do not translate to a human amount, and no such translation is offered here.
Selank peptide protocol in the clinical literature
The clinical Selank peptide protocol studied in Russia centered on a 0.15% aqueous intranasal solution applied as nasal drops. Generalized anxiety disorder and anxiety-asthenic trials administered it over multi-week courses — commonly on the order of two to three weeks — as an alternative or adjunct to benzodiazepine therapy [5]. One clinical study framed Selank as a way to optimize anxiety-disorder treatment, reporting anxiolytic benefit in patients [15]. These were supervised clinical investigations in diagnosed patients, not self-administration protocols, and they are described here only to convey how the compound was studied.
Selank nasal spray and routes studied
The Selank nasal spray (intranasal) route is the primary clinical route in the Russian literature, chosen because it delivers the peptide across the nasal mucosa and was the basis for the 0.15% clinical formulation [5]. Rodent research has additionally used intraperitoneal, subcutaneous, and intravenous routes for behavioral and pharmacokinetic work. The intranasal preference reflects both practicality and the peptide's poor oral survival; like all dosing detail here, the route information is reported as study methodology, not a usage instruction.
Stability, storage, and why frequency matters
Intact Selank is rapidly metabolized — its plasma half-life is on the order of minutes — but its metabolites retain biological activity, which is proposed to extend the functional duration of effect [2]. The C-terminal Pro-Gly-Pro extension is the design feature that slows enzymatic degradation relative to native tuftsin [13]. Research material is typically supplied lyophilized (freeze-dried), with reconstituted solutions kept refrigerated. The short half-life is a recurring theme in user reports of brief per-dose effects, covered on Selank effects; the pharmacokinetic detail itself is on the Selank half life page.
Why no human dose appears here
Selank is not approved by the FDA or any Western regulator, so there is no labeled human dose to report, and the research-chemical material sold outside Russia is not intended for human consumption. The published doses above belong to specific experiments in specific species and patient populations under supervision. Presenting them as a personal regimen would misrepresent both the evidence and the regulatory status, so this page stays strictly descriptive. For the safety reasoning behind that line, see Selank effects.